SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI.

Reduction in all‐cause death did not reach statistical significance (HR 0.87; 95% CI 0.59–1.28), whereas worsening HF events were less with dapagliflozin (HR 0.63; 95% CI 0.45–0.88; ARR 5%). 149 Cardiomyopathies and congenital heart disease Patients with infiltrative cardiomyopathies and with congenital heart disease were excluded from RCTs.

also in 111,027 other papers